Lung Cancer. 2014 Feb 3. pii: S0169-5002(14)00057-9. doi: 10.1016/j.lungcan.2014.01.021. [Epub ahead of print]

Surgery for malignant pleural mesothelioma: Why, when and what?

Lang-Lazdunski L.

Author information

• Department of Thoracic Surgery, 6th Floor Borough Wing, Guy's hospital, London SE1 9RT, UK; Division of Cancer Studies, King's College London, United Kingdom. Electronic address: loic.lang-lazdunski@gstt.nhs.uk.

Abstract

Malignant pleural mesothelioma is a fatal cancer developing in the pleural cavity, linked to asbestos exposure. Various therapies have been tried in the past 50 years including surgery, radiotherapy, chemotherapy, immunotherapy and more recently, targeted therapy. Radical surgery remains controversial in malignant pleural mesothelioma and two procedures have been offered in the past to obtain maximal cytoreduction: extrapleural pneumonectomy (EPP) and pleurectomy/decortication (P/D). Despite growing evidence that EPP might be detrimental, many believe that radical surgery should still be part of multimodality therapy in patients with malignant pleural mesothelioma. Recent evidence suggests that P/D is well tolerated and produces low mortality and morbidity. The role of adjuvant intrapleural therapies remains to be determined and evaluated in large prospective trials. Pleurectomy/decortication does not jeopardize the chance of having chemotherapy, or chemoradiotherapy either. Many now believe that it should be the default procedure in multimodality regimens. However, this remains to be proven in a large randomized trial. Palliative surgery still has an important role to play in mesothelioma, in establishing or refining diagnosis and in controlling symptoms and improving quality of life in many patients whose life expectancy is limited. Recent progress in molecular analyses and biomarkers should help with patient selection for surgery, immunotherapy and systemic therapies in the near future.